Skip to main content

Table 2 Hematologic and Non-Hematologic Toxicities related to treatment in the first two cycles

From: Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer

  

No.patients who experienced toxicity, at maximum grade per patient, at each dose level, mg/mq/die

Toxicity

NCIC-CTC grade

1500

1750

2000

2250

2500

2750

Nausea/vomiting

0

2

3

2

2

5

4

 

1

1

0

1

1

0

4

 

2

0

0

0

0

1

1

 

3*

0

0

0

0

0

0

 

4*

0

0

0

0

0

0

Diarrhoea

0

2

3

3

2

3

3

 

1

1

0

0

0

1

4

 

2

0

0

0

1

2

2

 

3*

0

0

0

0

0

0

 

4*

0

0

0

0

0

0

Liver Toxicity

0

3

2

3

2

6

6

 

1

0

1

0

1

0

3

 

2

0

0

0

0

0

0

 

3*

0

0

0

0

0

0

 

4*

0

0

0

0

0

0

Stomatitis

0

3

3

2

2

5

6

 

1

0

0

1

1

1

3

 

2

0

0

0

0

0

0

 

3*

0

0

0

0

0

0

 

4*

0

0

0

0

0

0

HFS

0

3

2

3

2

4

4

 

1

0

1

0

1

1

3

 

2

0

0

0

0

1

2

 

3*

0

0

0

0

0

0

 

4*

0

0

0

0

0

0

Fatigue

0

2

2

1

0

3

2

 

1

0

1

2

2

1

4

 

2

1

0

0

1

2

2

 

3*

0

0

0

0

0

0

 

4*

0

0

0

0

0

1

Leuco-neutropenia

0

2

2

2

2

3

6

 

1

0

1

0

0

1

1

 

2

1

0

1

1

0

1

 

3

0

0

0

0

1

1

 

4*

0

0

0

0

0

0

Thrombocytopenia

0

2

3

2

3

5

6

 

1

0

0

0

0

1

2

 

2

1

0

1

0

0

1

 

3

0

0

0

0

0

0

 

4*

0

0

0

0

0

0

Anemia

0

1

2

1

2

3

7

 

1

0

1

1

1

3

1

 

2

2

0

1

0

0

1

 

3

0

0

0

0

0

0

 

4*

0

0

0

0

0

0